Financials in Fixed Font
InterMune, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except per share amounts)
Three Months Ended Nine Months Ended
September 30, September 30,
2001 2000 2001 2000
Product sales
Actimmune, net $10,306 $3,831 $22,513 $6,964 (a)
Other, net 1,010 -- 2,373 --
Total net sales 11,316 3,831 24,886 6,964
Costs and expenses:
Cost of goods sold 3,915 1,457 10,514 3,397
Amortization of product
rights 815 557 3,990 1,777
Research and development 13,316 4,696 29,646 11,993
Selling, general and
administrative 9,438 2,992 22,850 7,689
Deferred compensation 823 2,056 3,068 5,127
Acquired in-process research
and development -- -- 5,400 --
Total costs and expenses 28,307 11,758 75,468 29,983
Loss from operations (16,991) (7,927) (50,582) (23,019)
Interest income, net 1,537 2,510 6,345 5,071
Net loss (15,454) (5,417) (44,237) (17,948)
Preferred stock accretion -- -- -- (269)
Redeemable preferred stock
dividend -- -- -- (27,762)
Net loss attributable to
common stockholders $(15,454) $(5,417) $(44,237) $(45,979)
Historical basic and diluted
net loss per share $(0.56) $(0.25) $(1.80) $(3.03)
Shares used in calculating
historical
basic and diluted net loss
per common share 27,390 21,757 24,532 15,169
Pro forma basic and diluted
net loss per share giving effect to
conversion of preferred
stock into common stock on
the Company's IPO $(0.56) $(0.25) $(1.80) $(2.41)
Shares used in calculating pro
forma basic and diluted net loss
per common share 27,390 21,757 24,532 18,944
Pro forma net loss
attributable to common stockholders
excluding acquired
in-process research
and development $(15,454) $(38,837)
Pro forma basic and diluted
net loss per share
excluding acquired
in-process research and
development $(0.56) $(1.58)
Shares used in calculating pro
forma net loss per share 27,390 24,532
(a) Sales of Actimmune(R) up to a contractual threshold of (in
thousands) $1,827 were reported by Connetics Corporation for the
respective period.
InterMune, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands)
September 30, December 31,
2001 2000
Cash, cash equivalents and
available-for-sale securities $396,190 $194,520
Other assets 54,555 7,129
Total assets $450,745 $201,649
Total liabilities $15,982 $5,848
Convertible subordinated notes 149,500 --
Stockholders' equity 285,263 195,801
Total liabilities and
stockholders' equity $450,745 $201,649
SOURCE InterMune, Inc. |
